Tosoh Corporation

Yokohama City University

Norihisa Ohtake

Noriaki Arakawa

Hisashi Hirano

Shohei Myoba

Hiroji Uemura

Etsuko Miyagi

Yusuke Ito

The present invention provides a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. According to the present invention, cancer (excluding castration-resistant prostate cancer) is detected by measuring the intact growth and differentiation factor (GDF15) propeptide level, the GDF15 propeptide fragment level, or the total of the intact GDF15 propeptide level and the GDF15 propeptide fragment level, in a sample. The above described method for detecting cancer includes a method for detecting one or more selected from the group consisting of stomach cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and esophageal cancer, and a method for distinguishing and detecting non-small cell lung cancer and small cell lung cancer. Further, a reagent for detecting cancer includes an antibody that specifically recognizes GDF15 propeptide.

Methods for detecting cancers, and detecting reagent

The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.

Method for detecting castration-resistant prostate cancer and detection reagent

The present invention aims to provide a method for detecting, with high sensitivity and specificity, ovarian clear cell adenocarcinoma, which is highly malignant, among benign and malignant ovarian tumors having various tissue types, and a reagent that can be used for the method. The present invention provides NT-TFPI2, which is a novel processed tissue factor pathway inhibitor 2 polypeptide, as a new detection marker for ovarian clear cell adenocarcinoma. The detection of ovarian clear cell adenocarcinoma is carried out by measuring the amount of NT-TFPI2, or the total amount of NT-TFPI2 and intact TFPI2. The reagent for detecting ovarian clear cell adenocarcinoma contains an antibody that specifically recognizes NT-TFPI2 and intact TFPI2.

Method and reagent for detecting ovarian clear cell adenocarcinoma

Growing community of inventors

Ayase, Japan

Norihisa Ohtake